Semaglutide as Adjunct Therapy for Adolescent Bariatric Surgery Patients

Adolescent obesity is a growing public health concern, often leading to severe health complications and reduced quality of life. For many adolescents with severe obesity, bariatric surgery is the most effective treatment, leading to significant and sustained weight loss. However, some patients may experience suboptimal weight loss or weight regain over time, highlighting a need for improved long-term outcomes. Current standard postoperative care focuses on behavioral interventions, but the potential for pharmacological adjuncts to enhance these outcomes remains underexplored. This Phase 1 trial specifically addresses the impact of adding semaglutide to standard postoperative care following bariatric surgery in adolescents.

As this is a Phase 1 trial that is currently recruiting participants, there are no specific findings or results to report yet. The study's primary objective is to evaluate the physiologic response to bariatric surgery when combined with semaglutide compared to standard postoperative care in adolescents. Researchers aim to determine if the addition of semaglutide can lead to improved body-weight trajectory and weight loss trajectory beyond what is achieved with standard care alone. They will also investigate the impact on body composition and various metabolic health markers. The core aim is to assess whether adjunct semaglutide can significantly enhance and sustain weight loss and metabolic improvements in adolescents after bariatric surgery.